Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 32
Filter
1.
Technol Health Care ; 24(6): 957-964, 2016 Nov 14.
Article in English | MEDLINE | ID: mdl-27259088

ABSTRACT

BACKGROUND: Osteoid osteoma is an osteoblastic benign bone tumor usually affecting young adolescents. Intra-articular lesions are not common; usually the diagnosis is delayed. A lot of studies report difficulties and complications in the management of osteoid osteoma of the hip joint using imaging guided techniques or open surgical procedures. Only few published cases have described that it can be treated precisely using hip arthroscopy. Additionally, the use of hip arthroscopy to apply the Chondrofiller®, an acellular collagen matrix for the management of articular cartilage defects of the hip joint, has not yet been described. CASE PRESENTATION: This report presents an osteoid osteoma of the femoral neck. A 20-year-old female professional basketball player presented with pain in the left groin since more than 12 months. On magnetic resonance and computed tomography imaging, an osteoid osteoma was suggested. The lesion was successfully removed using arthroscopy. During surgery, a concomitant grade 4 cartilage lesion on the femoral head was detected. For the treatment of this severe defect we used the Chondrofiller®, which is a new acellular collagen implant for auto-regeneration of articular cartilage. This matrix was filled into the prepared and dried defect using CO2 arthroscopy. After the hardening of the matrix the surgery was finished. The patient was pain free shortly after the operation and returned to sports within 16 weeks. Return to high-performance sports 8 months after surgery was without of any sign of complaints. CONCLUSIONS: This article demonstrates that hip arthroscopy is a valuable tool for biopsy and excision of intra-articular osteoid osteoma affecting the hip joint, as well as for addressing other concomitant pathologies such as a severe synovitis or cartilage defects. CO2 arthroscopy provided good conditions for the drying and filling of the cartilage defect with the Chondrofiller®.


Subject(s)
Arthroscopy/methods , Cartilage/transplantation , Femur Head/physiopathology , Femur Head/surgery , Hip Joint/surgery , Osteoma, Osteoid/diagnosis , Osteoma, Osteoid/surgery , Athletes , Basketball , Collagen , Female , Humans , Tomography, X-Ray Computed , Treatment Outcome , Young Adult
2.
J Transl Med ; 9: 168, 2011 Oct 04.
Article in English | MEDLINE | ID: mdl-21970318

ABSTRACT

BACKGROUND: In head and neck squamous cell carcinoma (HNSCC), expression levels of the epidermal growth factor receptor (EGFR) correlate with poor prognosis and decreased survival rates. As the mechanisms responsible for cellular immune response to EGFR in vivo remain unclear, the frequency and function of EGFR-specific cytotoxic T cells (CTL) was determined in HNSCC patients. METHODS: The frequency of CTL specific for the HLA-A2.1-restricted EGFR-derived YLN peptide (YLNTVQPTCV) and KLF peptide (KLFGTSGQKT) was determined in 16 HLA-A2.1+ HNSCC patients and 16 healthy HLA-A2.1+ individuals (NC) by multicolor flow cytometry. Patients' results were correlated to EGFR expression obtained by immunohistochemistry in corresponding tumor sections. Proliferation and anti-tumor activity of peptide-specific CTL was demonstrated by in vitro stimulation with dendritic cells pulsed with the peptides. RESULTS: Frequency of EGFR-specific CTL correlated significantly with EGFR expression in tumor sections (p = 0.02, r2 = 0.6). Patients with elevated EGFR scores (> 7) had a significantly higher frequency of EGFR-specific CTL than NC and patients with low EGFR scores (< 7). EGFR-specific CTL from cancer patients were expanded ex vivo and produced IFN-γ upon recognition of EGFR+ target cells. CONCLUSION: EGFR expressed on HNSCC cells induces a specific immune response in vivo. Strategies for expansion of EGFR-specific CTL may be important for future immunotherapy of HNSCC patients.


Subject(s)
Carcinoma, Squamous Cell/immunology , ErbB Receptors/metabolism , Head and Neck Neoplasms/immunology , T-Lymphocytes, Cytotoxic/immunology , CD8-Positive T-Lymphocytes/immunology , Carcinoma, Squamous Cell/pathology , Case-Control Studies , Cell Membrane/metabolism , Female , HLA-A2 Antigen/immunology , Head and Neck Neoplasms/pathology , Humans , Immunohistochemistry , Male , Middle Aged , Peptides/metabolism , Squamous Cell Carcinoma of Head and Neck
3.
J Biol Chem ; 286(22): 19576-88, 2011 Jun 03.
Article in English | MEDLINE | ID: mdl-21482821

ABSTRACT

Daxx is involved in transcriptional control and apoptosis. It comprises several domains, including a regulatory C terminus that is responsible for the interaction with numerous proteins such as p53, promyelocytic leukemia protein (PML), and Hsp27. Here, we describe the identification and characterization of two novel variants of Daxx termed Daxx-ß and Daxx-γ, which are generated by alternative splicing. Alternative splicing results in a truncated regulatory C terminus in both proteins. As a consequence, Daxx-ß and Daxx-γ show a markedly decreased affinity to PML, which in turn is associated with a different subnuclear localization of these proteins compared with Daxx. Although Daxx is localized mainly in PML-oncogenic domains (PODs) Daxx-ß and Daxx-γ display a distinct distribution pattern. Furthermore, Daxx-ß and Daxx-γ show a decreased affinity to p53 also due to the truncated C terminus. We provide evidence that the p53 recruitment into PODs is Daxx isoform-dependent. The decreased affinity of Daxx-ß/-γ to p53 and PML results in a diffuse localization of p53 throughout the nucleus. In contrast to Daxx, Daxx-ß and Daxx-γ are unable to repress p53-mediated transcription. Therefore, alternative splicing of Daxx might indicate an additional level in the cellular apoptosis network.


Subject(s)
Adaptor Proteins, Signal Transducing/biosynthesis , Alternative Splicing/physiology , Apoptosis/physiology , Cell Nucleus/metabolism , Nuclear Proteins/biosynthesis , Repressor Proteins/biosynthesis , Adaptor Proteins, Signal Transducing/genetics , Cell Nucleus/genetics , Co-Repressor Proteins , HEK293 Cells , HeLa Cells , Humans , Molecular Chaperones , Nuclear Proteins/genetics , Nuclear Proteins/metabolism , Promyelocytic Leukemia Protein , Protein Isoforms/biosynthesis , Protein Isoforms/genetics , Protein Structure, Tertiary , Repressor Proteins/genetics , Transcription Factors/genetics , Transcription Factors/metabolism , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism , Tumor Suppressor Proteins/genetics , Tumor Suppressor Proteins/metabolism
4.
BMC Cancer ; 10: 505, 2010 Sep 22.
Article in English | MEDLINE | ID: mdl-20860828

ABSTRACT

BACKGROUND: The cortical cytoskeleton network connects the actin cytoskeleton to various membrane proteins, influencing cell adhesion, polarity, migration and response to extracellular signals. Previous studies have suggested changes in the expression of specific components in prostate cancer, especially of 4.1 proteins (encoded by EPB41 genes) which form nodes in this network. METHODS: Expression of EPB41L1, EPB41L2, EPB41L3 (protein: 4.1B), EPB41L4B (EHM2), EPB41L5, EPB49 (dematin), VIL2 (ezrin), and DLG1 (summarized as "cortical cytoskeleton" genes) as well as ERG was measured by quantitative RT-PCR in a well-characterized set of 45 M0 prostate adenocarcinoma and 13 benign tissues. Hypermethylation of EPB41L3 and GSTP1 was compared in 93 cancer tissues by methylation-specific PCR. Expression of 4.1B was further studied by immunohistochemistry. RESULTS: EPB41L1 and EPB41L3 were significantly downregulated and EPB41L4B was upregulated in cancer tissues. Low EPB41L1 or high EPB41L4B expression were associated with earlier biochemical recurrence. None of the other cortical cytoskeleton genes displayed expression changes, in particular EPB49 and VIL2, despite hints from previous studies. EPB41L3 downregulation was significantly associated with hypermethylation of its promoter and strongly correlated with GSTP1 hypermethylation. Protein 4.1B was detected most strongly in the basal cells of normal prostate epithelia. Its expression in carcinoma cells was similar to the weaker one in normal luminal cells. EPB41L3 downregulation and EPB41L4B upregulation were essentially restricted to the 22 cases with ERG overexpression. Expression changes in EPB41L3 and EPB41L4B closely paralleled those previously observed for the extracellular matrix genes FBLN1 and SPOCK1, respectively. CONCLUSIONS: Specific changes in the cortical cytoskeleton were observed during prostate cancer progression. They parallel changes in the expression of extracellular matrix components and all together appear to be associated with oncogenic ERG overexpression. We hypothesize that these alterations may contribute to the increased invasivity conferred to prostate cancer cells by ERG deregulation.


Subject(s)
Cytoskeleton/metabolism , Extracellular Matrix/metabolism , Gene Expression Regulation, Neoplastic , Prostatic Neoplasms/genetics , Trans-Activators/biosynthesis , Actins/metabolism , Adenocarcinoma/genetics , Adenocarcinoma/metabolism , Aged , Cytoskeletal Proteins/biosynthesis , DNA Methylation , Disease Progression , Glutathione S-Transferase pi/biosynthesis , Humans , Immunohistochemistry , Male , Membrane Proteins/biosynthesis , Middle Aged , Neuropeptides/biosynthesis , Oncogenes , Prostatic Neoplasms/metabolism , Trans-Activators/genetics , Transcriptional Regulator ERG
5.
Am J Obstet Gynecol ; 203(3): e5-7, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20816142

ABSTRACT

Hailey-Hailey disease (HHD) is a rare, autosomal dominant intraepidermal blistering disorder characterized by recurrent vesicles and erosions affecting mostly the intertriginous areas. We report a case of HHD affecting exclusively the vulva from which an invasive squamous cell carcinoma developed after tacrolimus therapy.


Subject(s)
Carcinoma, Squamous Cell/pathology , Immunosuppressive Agents/adverse effects , Pemphigus, Benign Familial/drug therapy , Tacrolimus/adverse effects , Vulvar Diseases/drug therapy , Vulvar Neoplasms/pathology , Adult , Carcinoma, Squamous Cell/surgery , Female , Humans , Immunosuppressive Agents/administration & dosage , Lymph Node Excision , Tacrolimus/administration & dosage , Vulvar Neoplasms/surgery
6.
Tumour Biol ; 31(4): 297-307, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20506051

ABSTRACT

Many metastatic cancers recapitulate the epithelial-to-mesenchymal transition (EMT) resulting in enhanced cell motility and invasiveness. The EMT is regulated by several transcription factors, including the zinc finger protein SNAI2, also named Slug, which appears to exert additional functions during development and cancer progression. We have studied the function of SNAI2 in prostate cancer cells. Quantitative RT-PCR analysis showed strong SNAI2 expression particularly in the PC-3 and PC3-16 prostate carcinoma cell lines. Knockdown of SNAI2 by specific siRNA induced changes in EMT markers and inhibited invasion of both cell lines into a matrigel matrix. SNAI2 siRNA-treated cells did not tolerate detachment from the culture plates, likely at least in part due to downregulation of integrin alpha6beta4. SNAI2 knockdown disturbed the microtubular and actin cytoskeletons, especially severely in PC-3 cells, resulting in grossly enlarged, flattened, and sometimes multinuclear cells. Knockdown also decreased cell proliferation, with a prominent G0/G1 arrest in PC3-16. Together, our data imply that SNAI2 exerts strong effects on the cytoskeleton and adhesion of those prostate cancer cells that express it and is necessary for their proliferation and invasiveness.


Subject(s)
Cell Proliferation , Prostatic Neoplasms/pathology , Transcription Factors/physiology , Actins/metabolism , Apoptosis/drug effects , Blotting, Western , Cell Adhesion , Cell Cycle , Cells, Cultured , Cytoskeleton/metabolism , Gene Silencing , Humans , Integrin alpha6beta4/metabolism , Male , Neoplasm Invasiveness , Prostatic Neoplasms/genetics , Prostatic Neoplasms/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA, Small Interfering/pharmacology , Reverse Transcriptase Polymerase Chain Reaction , Snail Family Transcription Factors , Zinc Fingers
7.
Cancer Genomics Proteomics ; 7(2): 51-60, 2010.
Article in English | MEDLINE | ID: mdl-20335518

ABSTRACT

BACKGROUND: Imprinted genes are often arranged in clusters epigenetically controlled by differentially methylated regions (DMR) containing bivalent histone modifications. Both DNA hypermethylation and hypomethylation in cancer can therefore disturb imprinted gene expression. We have studied expression, DNA methylation and histone modifications of TFPI2, a presumed tumor suppressor, and that of other genes in the 7q21 imprinted gene cluster in prostate cancer. MATERIALS AND METHODS: TFPI, TFPI2, SGCE and PON2 expression were assessed by qRT-PCR in prostate cancer tissues and cell lines. DNA methylation and histone modifications were investigated by bisulphite sequencing and chromatin immunoprecipatation. RESULTS: TFPI2 was highly variably expressed in cancer tissues, in contrast to TFPI, and did not correlate to unchanged SGCE and significantly elevated PON2 expression. TFPI2 expression variations were unrelated to global DNA hypomethylation, but were associated with promoter methylation. PC3 cells with high expression retained normal methylation and bivalent histone modifications at DMR and promoter, whereas low-expressing LNCaP cells presented aberrant DNA methylation and more repressive histone modifications. CONCLUSION: Epigenetic disturbances in the 7q21 cluster affect imprinted genes in a non-coordinate manner suggesting an unstable epigenetic state prone to selection for specific expression changes.


Subject(s)
Gene Silencing , Genomic Imprinting/genetics , Glycoproteins/genetics , Placenta/metabolism , Prostatic Neoplasms/genetics , Cell Line, Tumor , Chromatin Immunoprecipitation , Chromosomes, Human, Pair 7/genetics , CpG Islands/genetics , DNA Methylation/genetics , Female , Gene Expression Regulation, Neoplastic , Glycoproteins/metabolism , Histones/metabolism , Humans , Male , Multigene Family/genetics , Neoplasm Proteins/genetics , Neoplasm Proteins/metabolism , Pregnancy , Promoter Regions, Genetic/genetics , Protein Processing, Post-Translational , RNA, Messenger/genetics , RNA, Messenger/metabolism
8.
Hypertens Res ; 33(5): 467-72, 2010 May.
Article in English | MEDLINE | ID: mdl-20186151

ABSTRACT

Adrenal adenomas producing both aldosterone and cortisol (A/CPAs) have been described in only a few cases. Correct subtype classification is necessary for making therapeutic decisions in primary aldosteronism (PA). Therefore, we studied in detail the clinical, hormonal and histological features of this entity in two patients with A/CPAs. We describe two patients with A/CPA and present their endocrine evaluations at baseline, after suppression with fludrocortisone and dexamethasone, after therapy with spironolactone and after unilateral adrenalectomy. Moreover, the expression of corticotropin (MC2R) and angiotensin II type 1 (AT1R) receptors and 17alpha-hydroxylase in the tumors of these two patients was analyzed by immunohistochemistry. Aldosterone, 18-hydroxycorticosterone (18-OH-B) and 18-hydroxycortisol (18-OH-F) were not suppressible with fludrocortisone in either patient and were partly suppressible with dexamethasone in one of the patients. Adrenal insufficiency developed in both patients after operation and lasted for more than 6 months. Aldosterone and hybrid corticosteroids returned to normal 8 weeks after adrenalectomy. In both cases, immunostaining showed weak expression of AT1R and MC2R but strong expression of 17alpha-hydroxylase. The most common germline mutations in the aldosterone synthase gene and the aldosterone synthase/11beta-hydroxylase hybrid gene were absent. These two cases document the fact that sporadic A/CPA is a subtype of PA. The presence of an A/CPA should be considered if a patient has both PA and hypercortisolism.


Subject(s)
Adrenal Cortex Neoplasms/metabolism , Adrenocortical Adenoma/metabolism , Aldosterone/metabolism , Hydrocortisone/metabolism , Hyperaldosteronism/physiopathology , Adrenal Cortex Neoplasms/genetics , Adrenal Cortex Neoplasms/surgery , Adrenocortical Adenoma/genetics , Adrenocortical Adenoma/surgery , Blotting, Western , Cytochrome P-450 CYP11B2/genetics , Female , Humans , Hyperaldosteronism/genetics , Hyperaldosteronism/surgery , Immunoassay , Immunohistochemistry , Middle Aged , Steroid 17-alpha-Hydroxylase/genetics , Treatment Outcome
9.
Clin Cancer Res ; 16(3): 790-9, 2010 Feb 01.
Article in English | MEDLINE | ID: mdl-20103678

ABSTRACT

PURPOSE: Epidermal growth factor receptor (EGFR) antibody therapy is established in patients with wild-type KRAS colorectal carcinoma; however, up to 50% of these patients do not respond to this therapy. To identify the possible causes of this therapy failure, we searched for mutations in different EGFR-dependent signaling proteins and analyzed their distribution patterns in primary tumors and corresponding metastases. EXPERIMENTAL DESIGN: Tumor tissues, macrodissected from tumor centers, invasion fronts (n = 100), lymph nodes (n = 55), and distant metastases (n = 20), respectively, were subjected to DNA extraction and mutation analysis of KRAS, BRAF, and PIK3CA. RESULTS: Activating mutations were detected in 41% (KRAS), 7% (BRAF), and 21% (PIK3CA) of the primary tumors. By comparing tumor centers and invasion fronts, the intratumoral heterogeneity of KRAS, BRAF, and PIK3CA mutations was observed in 8%, 1%, and 5% of primary tumors, respectively. Heterogeneity between primary tumors and lymph node metastases was found in 31% (KRAS), 4% (BRAF), and 13% (PIK3CA) of the cases. Heterogeneity between primary tumors and distant metastases was present in two patients (10%) for KRAS and one patient for PIK3CA (5%), but not for BRAF. Discordant results between primary tumors and metastases could markedly be reduced by testing the additional tumor samples. CONCLUSIONS: Failure of EGFR antibody therapy in patients with wild-type KRAS colorectal cancer may result from activating BRAF or PIK3CA mutations and false-negative sequencing results caused by intratumoral heterogeneity. Due to the particularly high rates of heterogeneity between primary tumors and lymph node metastases, the latter are least suitable for diagnostic mutation analysis.


Subject(s)
Adenocarcinoma/genetics , Colorectal Neoplasms/genetics , Genes, ras , Mutation , Neoplasm Metastasis/genetics , Phosphatidylinositol 3-Kinases/genetics , Proto-Oncogene Proteins B-raf/genetics , Adolescent , Adult , Aged , Aged, 80 and over , Class I Phosphatidylinositol 3-Kinases , Colorectal Neoplasms/pathology , Female , Genetic Variation , Humans , Lymphatic Metastasis/genetics , Male , Middle Aged
10.
Auris Nasus Larynx ; 37(3): 322-8, 2010 Jun.
Article in English | MEDLINE | ID: mdl-19857939

ABSTRACT

OBJECTIVE: Five cases of rhinocerebral mucormycosis (RCM) with different courses of illness and outcomes also due to different therapeutical strategies including Posaconazole as a new therapeutic option are described. Predisposing conditions for RCM are diabetes mellitus and immunosuppression. Diagnosis is often delayed because patients complain about nonspecific symptoms of acute rhinosinusitis, and initial CT imaging is unimpressive. Progressive disease, however, leads to early orbital and cerebral invasion. Due to the lack of typical clinical signs, diagnosis relies on histopathology. Therapy consists of the management of predisposing factors, radical surgical intervention and systemic antifungal therapy. METHODS: We describe five cases of RCM with different comorbidities and outcomes. RESULTS: RCM remains a diagnostic and therapeutic challenge because it begins with nonspecific symptoms and ends as fulminant disease with high mortality. Here, systemic treatment with Posaconazole appears to be a more effective alternative to amphotericin. CONCLUSION: If a patient is suspected having RCM, improvement of predisposing diseases, radical surgical debridement and effective systemic antifungal therapy must be instituted immediately.


Subject(s)
Antifungal Agents/therapeutic use , Central Nervous System Bacterial Infections/drug therapy , Central Nervous System Bacterial Infections/microbiology , Mucormycosis/complications , Mucormycosis/drug therapy , Rhinitis/drug therapy , Rhinitis/microbiology , Triazoles/therapeutic use , Aged , Female , Humans , Male , Severity of Illness Index
11.
Head Face Med ; 5: 25, 2009 Nov 24.
Article in English | MEDLINE | ID: mdl-19930688

ABSTRACT

Desmoplastic fibroma (DF) is a rare, benign but locally aggressive, intraosseous lesion with a high tendency of local recurrence. In this report the actual literature is reviewed regarding epidemiological data, pathology, clinical diagnostic criterias, therapy and prognosis. Moreover, a report of an interesting case is included localized in the mandibular corpus.


Subject(s)
Fibroma, Desmoplastic/diagnosis , Mandibular Neoplasms/diagnosis , Adult , Diagnosis, Differential , Fibroma, Desmoplastic/pathology , Fibroma, Desmoplastic/surgery , Humans , Magnetic Resonance Imaging , Male , Mandibular Neoplasms/pathology , Mandibular Neoplasms/surgery , Radiography, Panoramic
12.
J Urol ; 182(6): 2920-5, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19846140

ABSTRACT

PURPOSE: EZH2 increases the proliferation rate and apoptosis resistance of renal cell carcinoma cell lines. To date its clinical impact on the outcome in patients with renal cell carcinoma is not known. To our knowledge this is the first study of the association of EZH2 expression with histopathological features and disease outcomes in a large cohort of patients who underwent surgery for renal cell carcinoma. MATERIALS AND METHODS: Real-time reverse transcriptase-polymerase chain reaction was done to quantify EZH2 expression in malignant and adjacent benign renal tissue from a cohort of 119 patients with clear cell renal cell carcinoma. Median followup was 51 months. Immunohistochemistry was performed in a subset of samples. The impact of EZH2 expression on clinicopathological tumor features and outcome was investigated. RESULTS: EZH2 was over expressed in renal cell carcinoma compared to adjacent benign renal parenchyma (median 57.02, range 0 to 368.11 vs 0, range 0 to 280.87, p <0.001). Immunohistochemistry showed concordant results and revealed EZH2 protein predominantly located in the nucleus. EZH2 expression was not associated with histopathological tumor features and patient characteristics. High EZH2 levels predicted a lower disease recurrence rate on univariate and multivariate analysis (p = 0.047 and 0.037, respectively). CONCLUSIONS: These data support a role of EZH2 expression for renal cell carcinoma tumorigenesis rather than tumor progression. Contrary to previous EZH2 findings in cases of various human malignancies, high tumor EZH2 levels appear to indicate less aggressive tumor phenotypes with a favorable prognosis in renal cell carcinoma cases. Our findings suggest that EZH2 provides not only a potential therapeutic target, but also a molecular parameter for outcome prediction in patients with renal cell carcinoma.


Subject(s)
Carcinoma, Renal Cell/metabolism , DNA-Binding Proteins/biosynthesis , Kidney Neoplasms/metabolism , Transcription Factors/biosynthesis , Adult , Aged , Aged, 80 and over , Carcinoma, Renal Cell/surgery , Enhancer of Zeste Homolog 2 Protein , Female , Humans , Kidney Neoplasms/surgery , Male , Middle Aged , Polycomb Repressive Complex 2 , Prognosis , Prospective Studies
13.
J Med Case Rep ; 3: 8583, 2009 Jul 23.
Article in English | MEDLINE | ID: mdl-19830233

ABSTRACT

INTRODUCTION: Seborrheic keratoses are very common findings in elderly patients. However, a sudden onset and dramatic increase in the number and size of these benign lesions deserves special attention, since this may represent the Leser Trélat sign, a rare paraneoplastic cutaneous syndrome. CASE PRESENTATION: A 92-year-old female presented to our clinic with multiple eruptive seborrheic keratoses, which had dramatically increased in size and number over the past two years. A diagnostic work-up revealed an ovarian carcinoma. Hence, cutaneous findings in our patient were consistent with the diagnosis of the Leser-Trélat sign. CONCLUSION: The Leser-Trélat sign may coincide with the diagnosis of occult cancer or follow or precede it by months or years. Practitioners should take cases of eruptive seborrheic keratoses seriously and perform thorough patient examinations.

14.
Neoplasia ; 11(7): 651-61, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19568410

ABSTRACT

Recent studies have demonstrated that the chemokine receptor CXCR4 plays a crucial role in organ-specific metastasis formation. Although a variety of studies showed the expression of chemokine receptors, in particular, CXCR4, by gastrointestinal tumors, the precise mechanisms of chemokine receptor-mediated homing of cancer cells to specific sites of metastasis remained elusive. Here, we used liver metastatic human HEP-G2 hepatoma and HT-29LMM colon cancer cells expressing functional CXCR4 to dissect the metastatic cascade by intravital fluorescence microscopy. Immunohistochemistry revealed that the CXCR4 ligand CXCL12 is expressed by endothelial cells and likely Kupffer cells lining the liver sinusoids. Tumor cell adhesion and extravasation in vivo was quantitatively analyzed using intravital fluorescence microscopy. Treatment of cells with an anti-CXCR4 antibody did not affect cell adhesion but significantly impaired tumor cell extravasation (HEP-G2; isotype control: 22.3% +/- 4.3% vs anti-CXCR4: 6.0% +/- 5.0%, P < .001). In addition, pretreatment of tumor cells with the ligand CXCL12 enhanced the activation of the small GTPases Rho, Rac, and cdc42 as well as tumor cell extravasation without affecting tumor cell adhesion within liver sinusoids. Taken together, the findings of the present study provide first in vivo insights into the early events of chemokine ligand/receptor-mediated liver metastasis formation of tumor cells and define tumor cell extravasation rather than tumor cell arrest as the rate-limiting event.


Subject(s)
Chemokine CXCL12/metabolism , Neoplasm Invasiveness/pathology , Neoplasm Metastasis/pathology , Receptors, CXCR4/metabolism , Cell Adhesion/physiology , Cell Line, Tumor , Colorectal Neoplasms/metabolism , Colorectal Neoplasms/pathology , Flow Cytometry , Humans , Immunohistochemistry , Liver Neoplasms/metabolism , Liver Neoplasms/secondary , Microscopy, Fluorescence , Reverse Transcriptase Polymerase Chain Reaction
16.
Mol Reprod Dev ; 75(9): 1484-94, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18271004

ABSTRACT

Frasier syndrome (FS) is characterized by chronic renal failure in early adulthood, varying degrees of gonadal dysgenesis, and a high risk for gonadal germ cell malignancies, particularly gonadoblastoma. Although it is known to arise from heterozygous splice mutations in intron 9 of the Wilms' tumor gene 1 (WT1), the mechanisms by which these mutations result in gonadal dysgenesis in humans remain obscure. Here we show that a decrease in WT1 + KTS isoforms due to disruption of alternative splicing of the WT1 gene in a FS patient is associated with diminished expression of the transcription factors SRY and SOX9 in Sertoli cells. These findings provide the first confirmation in humans of the results obtained by others in mice. Consequently, Sertoli cells fail to form the specialized environment within the seminiferous tubules that normally houses developing germ cells. Thus, germ cells are unable to fully mature and are blocked at the spermatogonial-spermatocyte stage. Concomitantly, subpopulations of the malignant counterpart of primordial germ cells/gonocytes, the intratubular germ cell neoplasia unclassified type (ITGCN), are identified. Furthermore, dysregulated Leydig cells produce insufficient levels of testosterone, resulting in hypospadias. Collectively, the impaired spermatogenesis, hypospadias and ITGCN comprise part of the developmental disorder known as 'testicular dysgenesis syndrome' (TDS), which arises during early fetal life. The data presented here show that critical levels of WT1 + KTS, SRY and SOX9 are required for normal Sertoli cell maturation, and subsequent normal spermatogenesis. To further study the function of human Sertoli cells in the future, we have established a human cell line.


Subject(s)
Frasier Syndrome/genetics , Gonadal Dysgenesis/complications , High Mobility Group Proteins/genetics , Sex-Determining Region Y Protein/genetics , Testicular Diseases/complications , Transcription Factors/genetics , Adult , Cells, Cultured , Child , DNA Mutational Analysis , Down-Regulation , Frasier Syndrome/complications , Frasier Syndrome/metabolism , Frasier Syndrome/pathology , Genes, Wilms Tumor , Gonadal Dysgenesis/genetics , Gonadal Dysgenesis/metabolism , High Mobility Group Proteins/metabolism , Humans , Lysine/genetics , Male , Mutation , RNA, Messenger/metabolism , SOX9 Transcription Factor , Serine/genetics , Sex-Determining Region Y Protein/metabolism , Spermatogenesis/genetics , Testicular Diseases/genetics , Testicular Diseases/metabolism , Threonine/genetics , Transcription Factors/metabolism
17.
Hum Pathol ; 39(5): 701-9, 2008 May.
Article in English | MEDLINE | ID: mdl-18304605

ABSTRACT

Testicular granulosa cell tumors (GCTs) are very rare neoplasms. Although adult GCTs are thought to have a relatively indolent course, several reports have demonstrated the malignant potential of these lesions. In case of distant metastases, the overall survival is very short. To date, there is no well-established treatment for these tumors owing to poor results and very rapid progression. A 55-year-old male patient was diagnosed with a testicular GCT with distant lung metastases. He underwent surgical treatment with orchiectomy and adjuvant polychemotherapy (cisplantine, etoposide, and bleomycine) as well as metastasectomy of the right lung. We report the first case of a successfully treated testicular GCT with bipulmonary metastases at initial diagnosis. Thirty-nine months after treatment, the patient is alive with no evidence of disease. We subsequently reviewed all reported cases of an adult GCT in the published literature (25 published cases). This review will summarize all reported cases and discuss treatment options. The current case suggests that a combination of varying treatment modalities could be a promising and reasonable way to manage malignant advanced GCT of the adult testis.


Subject(s)
Granulosa Cell Tumor/pathology , Testicular Neoplasms/pathology , Adolescent , Adult , Aged , Combined Modality Therapy , Granulosa Cell Tumor/therapy , Humans , Lung Neoplasms/secondary , Lung Neoplasms/therapy , Male , Middle Aged , Testicular Neoplasms/therapy
18.
Wien Klin Wochenschr ; 120(23-24): 723-31, 2008.
Article in German | MEDLINE | ID: mdl-19122982

ABSTRACT

The management of soft tissue sarcoma has evolved from a solitary surgical treatment to an interdisciplinary multimodal approach including radiotherapy. These fundamental changes are the result of increased knowledge in tumor biology, radiation sensitivity and the improvement in modern radiation therapy techniques. A successful effective therapy regimen strongly depends on distinct preoperative diagnostics, preoperative conception of the surgical intervention and an experienced oncological team. Of significant importance for the prognosis is early diagnosis as well as tumor excision with a wide negative margin. However, even after complete wide resection in sano, the use of postoperative radiotherapy can further improve local control and should therefore be applied to the majority of patients. Consequently, radiotherapy should only be omitted in cases in which the tumor has been excised with a very wide negative margin; this implies, however, high quality of surgery and distinct histopathological analysis. Patients with non- or questionable resectable tumors, should be referred for pre-operative radiotherapy in order to improve the surgical results. Recent studies have underlined the efficiency of modern radiotherapy regimens. The different radiotherapy regimens will be highlighted against the background of tumor stage and tumor resectibility.


Subject(s)
Patient Care Team , Sarcoma/radiotherapy , Brachytherapy , Combined Modality Therapy , Dose Fractionation, Radiation , Early Diagnosis , Humans , Neoadjuvant Therapy , Neoplasm Staging , Radiotherapy Planning, Computer-Assisted , Radiotherapy, Adjuvant , Sarcoma/diagnosis , Sarcoma/pathology , Sarcoma/surgery
20.
Prostate ; 67(16): 1770-80, 2007 Dec 01.
Article in English | MEDLINE | ID: mdl-17929269

ABSTRACT

BACKGROUND: Fibulins, encoded by FBLN genes, are extracellular matrix proteins influencing cell adhesion and migration. Altered expression of fibulins is associated with progression of several cancer types, but has not been studied in prostate cancer. METHODS: Expression of FBLN1 (major splice forms C and D), FBLN4, FBLN5, SPOCK1, and TENC was compared between 47 prostate cancer samples and 13 benign prostatic tissues by quantitative RT-PCR. Fibulin-1 and fibulin-5 expression was studied by immunohistochemistry. Effects of androgens and the DNA methylation inhibitor 5-aza-2'-deoxycytidine on fibulin expression were investigated in different prostate cancer cell lines. RESULTS: Our recent microarray analysis suggested downregulation of three fibulins, FBLN1, FBLN4, and FBLN5, in prostate cancer, while two further ECM genes, SPOCK1 (testican) and TENC (tenascin C), appeared upregulated or unchanged. These observations were corroborated by quantitative RT-PCR. Accordingly, FBLN1 and FBLN4 were weakly expressed in carcinoma lines compared to normal prostate epithelial cells (PrECs). Only FBLN4 was induced by 5-aza-2'-deoxycytidine, but its promoter was unmethylated. Androgen did not affect expression of FBLN genes. The FBLN1C and FBLN1D splice forms were coordinately expressed. Fibulin-1 protein was weakly detectable in benign PrECs, but tended to accumulate in cancer cells. Fibulin-5 was predominantly located in the stroma with a strong gradient from the periurethral to the peripheral zone, and lost in cancers. CONCLUSIONS: Three FBLN genes are significantly downregulated in prostate cancer, whereas SPOCK1 is often upregulated. FBLN5 downregulation fits its postulated anticancerous function, whereas FBLN1 and FBLN4 behave different than in certain other cancers.


Subject(s)
Extracellular Matrix Proteins/genetics , Gene Expression Regulation, Neoplastic , Prostatic Neoplasms/genetics , Aged , Azacitidine/analogs & derivatives , Azacitidine/pharmacology , Calcium-Binding Proteins/biosynthesis , Calcium-Binding Proteins/genetics , Calcium-Binding Proteins/metabolism , Cell Line, Tumor , DNA Methylation/drug effects , Decitabine , Down-Regulation , Extracellular Matrix Proteins/biosynthesis , Extracellular Matrix Proteins/metabolism , Gene Dosage , Gene Expression Profiling/methods , Humans , Immunohistochemistry , Male , Middle Aged , Prostatic Neoplasms/metabolism , Proteoglycans/biosynthesis , Proteoglycans/genetics , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Reverse Transcriptase Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL
...